GlassScriptPhysician profile
Danny H Cho
NPI 1962441014
$17,449.60
in general payments reported to CMS, 2019-2025
59 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $1,607 · 2021: $2,494 · 2022: $2,611 · 2023: $2,795 · 2024: $2,857 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,593 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,592.96 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,195.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,756.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,520.52 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,467.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,351.39 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Lilly USA, LLC | $1,231.07 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,019.23 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $810.79 | 2019-2024 | Xarelto |
| Pfizer INC. | $608.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $448.85 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $435.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $393.48 | 2022-2025 | |
| Dexcom, INC. | $365.89 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $328.91 | 2021-2025 | Freestyle Libre 3, Jot Dx |
| Merck Sharp & Dohme LLC | $290.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.